Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epcoritamab + Lenalidomide + Rituximab in R/R PCNSL
NCT06931652Phase 2Recruiting
- Sponsor
- LYSARC
- Start
- Sep 2025
- Primary completion
- Jan 2028
- Modality
- Antibody Conjugates, Bispecific Antibodies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of epcoritamab in primary central nervous system lymphoma (PCNSL), sponsored by LYSARC. Started Sep 2025; status: recruiting.
02
Drugs
epcoritamab
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT06931652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06931652.